Strepsils Max Pro

Loz: Symptomatic relief of sore throat. Oromucosal spray: Short-term symptomatic relief of acute sore throat.

Loz Adult, elderly & childn >12 yr 1 loz dissolved slowly in mouth every 3-6 hr. Max: 5 loz/24 hr for 3 days. Oromucosal spray Adult ≥18 yr 3 sprays to the back of the throat every 3-6 hr up to max: 5 doses in 24-hr period. Max duration: 3 days.

Hypersensitivity to flurbiprofen, aspirin or other NSAIDs. Active, existing or history of recurrent peptic ulcerations/haemorrhage. History of GI bleeding or perforation related to previous NSAIDs therapy. Severe heart, renal or hepatic failure. Last trimester of pregnancy. Oromucosal spray: Active or history of recurrent intestinal ulceration. History of severe colitis, haemorrhagic or haematopoietic disorders related to previous NSAID therapy. Childn & adolescents <18 yr.

Discontinue use if GI bleeding, ulceration, 1st appearance of skin rash, mucosal lesions, any other sign of hypersensitivity or bacterial infection occur. Previous history of bronchial asthma or allergic disease; HTN &/or heart failure, GI disease eg, ulcerative colitis, Crohn's disease. SLE & mixed connective tissue disease; cardiac impairment. Avoid use w/ NSAIDs including selective COX-2 inhibitors. Concomitant use of oral corticosteroids, anticoagulants (eg, warfarin), SSRIs, anti-platelet agents (eg, ASA); diuretics. Renal impairment & mild to moderate hepatic dysfunction. Avoid use during 1st 6 mth of pregnancy. Elderly or debilitated patients. Loz: Serious skin reactions eg, exfoliative dermatitis, SJS, TEN. Not to be taken by patients w/ fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency. Oromucosal spray: Discontinue use if mouth irritation occurs. Not to be used perioperatively in patients who have recently undergone CABG surgery & revascularization procedures. Exacerbation of infective inflammations eg, development of necrotising fasciitis; purulent bacterial pharyngitis/tonsillitis. Fluid retention & oedema; GI toxicity; serious GI events & other risk factors associated w/ PUD eg, alcoholism, smoking; abnormal bleeding; analgesic-induced headache. May cause allergic reactions due to methyl- & propyl parahydroxybenzoate. High-dose & long-term use. May impair female fertility. Not recommended during lactation.

Dizziness, headache, paresthesia; throat irritation; diarrhoea, mouth ulceration, nausea, oral pain, paraesthesia & discomfort, oropharyngeal pain. Oromucosal spray: Hypersensitivity reactions, oedema, HTN, cardiac failure.

Increased adverse events w/ other NSAIDs including COX-2 selective inhibitors, low-dose ASA. Enhanced effects of anticoagulants eg, warfarin. Increased risk of GI ulceration or bleeding w/ antiplatelet agents, SSRIs. Reduced effects of antihypertensives, diuretics, mifepristone. Increased risk of adverse reactions w/ alcohol, corticosteroids. Exacerbated cardiac failure, reduced GFR & increased plasma glycoside levels w/ cardiac glycosides. Increased risk of nephrotoxicity w/ ciclosporin, tacrolimus. Increased lithium, phenytoin serum levels. Elevated MTX conc. Altered blood glucose levels w/ oral antidiabetics. Hyperkalaemia w/ K-sparing diuretics. Delayed excretion w/ probenecid, sulfinpyrazone. Increased risk of developing convulsions w/ quinolones. Increased risk of haematological toxicity w/ zidovudine.

Preparations for Oral Ulceration & Inflammation

R02AX01 - flurbiprofen ; Belongs to the class of other throat preparations.

C